• Something wrong with this record ?

Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension

O. Gawrys, P. Kala, J. Sadowski, V. Melenovský, P. Sandner, L. Červenka

. 2025 ; 987 (-) : 177175. [pub] 20241205

Language English Country Netherlands

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25002836

Nitric oxide (NO)-stimulated cyclic guanosine monophosphate (cGMP) is a key regulator of cardiovascular health, as NO-cGMP signalling is impaired in diseases like pulmonary hypertension, heart failure and chronic kidney disease. The development of NO-independent sGC stimulators and activators provide a novel therapeutic option to restore altered NO signalling. sGC stimulators have been already approved for the treatment of pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and chronic heart failure (HFrEF), while sGC activators are currently in phase-2 clinical trials for CKD. The best characterized effect of increased cGMP via the NO-sGC-cGMP pathway is vasodilation. However, to date, none of the sGC agonists are in development for hypertension (HTN). According to WHO, the global prevalence of uncontrolled HTN continues to rise, contributing significantly to cardiovascular mortality. While there are effective antihypertensive treatments, many patients require multiple drugs, and some remain resistant to all therapies. Thus, in addition to improved diagnosis and lifestyle changes, new pharmacological strategies remain in high demand. In this review we explore the potential of sGC stimulators and activators as novel antihypertensive agents, starting with the overview of NO-sGC-cGMP signalling, followed by potential mechanisms by which the increase in cGMP may regulate vascular tone and BP. These effects may encompass not only acute vasodilation, but also mid-term and chronic effects, such as the regulation of salt and water balance, as well as mitigation of vascular ageing and remodelling. The main section summarizes the preclinical and clinical evidence supporting the BP-lowering efficacy of sGC agonists.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002836
003      
CZ-PrNML
005      
20250206103909.0
007      
ta
008      
250121e20241205ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejphar.2024.177175 $2 doi
035    __
$a (PubMed)39645219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Gawrys, Olga $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: olga.gawrys@ikem.cz
245    10
$a Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension / $c O. Gawrys, P. Kala, J. Sadowski, V. Melenovský, P. Sandner, L. Červenka
520    9_
$a Nitric oxide (NO)-stimulated cyclic guanosine monophosphate (cGMP) is a key regulator of cardiovascular health, as NO-cGMP signalling is impaired in diseases like pulmonary hypertension, heart failure and chronic kidney disease. The development of NO-independent sGC stimulators and activators provide a novel therapeutic option to restore altered NO signalling. sGC stimulators have been already approved for the treatment of pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and chronic heart failure (HFrEF), while sGC activators are currently in phase-2 clinical trials for CKD. The best characterized effect of increased cGMP via the NO-sGC-cGMP pathway is vasodilation. However, to date, none of the sGC agonists are in development for hypertension (HTN). According to WHO, the global prevalence of uncontrolled HTN continues to rise, contributing significantly to cardiovascular mortality. While there are effective antihypertensive treatments, many patients require multiple drugs, and some remain resistant to all therapies. Thus, in addition to improved diagnosis and lifestyle changes, new pharmacological strategies remain in high demand. In this review we explore the potential of sGC stimulators and activators as novel antihypertensive agents, starting with the overview of NO-sGC-cGMP signalling, followed by potential mechanisms by which the increase in cGMP may regulate vascular tone and BP. These effects may encompass not only acute vasodilation, but also mid-term and chronic effects, such as the regulation of salt and water balance, as well as mitigation of vascular ageing and remodelling. The main section summarizes the preclinical and clinical evidence supporting the BP-lowering efficacy of sGC agonists.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    12
$a hypertenze $x farmakoterapie $x patofyziologie $7 D006973
650    12
$a rozpustná guanylátcyklasa $x metabolismus $7 D000071756
650    12
$a antihypertenziva $x terapeutické užití $x farmakologie $7 D000959
650    12
$a guanosinmonofosfát cyklický $x metabolismus $7 D006152
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a agonisté guanylátcyklasy $x terapeutické užití $x farmakologie $7 D000074268
650    _2
$a aktivátory enzymů $x terapeutické užití $x farmakologie $7 D020536
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kala, Petr $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Cardiology, Motol University Hospital and Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Sadowski, Janusz $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Sandner, Peter $u Bayer AG, Pharmaceuticals, Drug Discovery, Pharma Research Centre, 42113, Wuppertal, Germany; Hannover Medical School, Institute of Pharmacology, 30625, Hannover, Germany
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Department of Internal Medicine, Cardiology, Olomouc University Hospital and Palacký University, Olomouc, Czech Republic
773    0_
$w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 987 (20241205), s. 177175
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39645219 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103905 $b ABA008
999    __
$a ok $b bmc $g 2262937 $s 1238843
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 987 $c - $d 177175 $e 20241205 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options